Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.97 USD | +0.02% | +0.05% | +240.87% |
05-10 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
05-09 | Alpine Immune Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+240.87% | 4.46B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- ALPN Stock
- News Alpine Immune Sciences, Inc.
- Oppenheimer Raises Alpine Immune Sciences Price Target to $44 From $33, Maintains Outperform Rating